Seeking Alpha

MannKind (MNKD): Q3 EPS of -$0.42 beats by $0.06, on no revenue. "While we continue to be fully...

MannKind (MNKD): Q3 EPS of -$0.42 beats by $0.06, on no revenue. "While we continue to be fully engaged in the task of navigating our NDA through the FDA review process, we are continuing to run additional studies of AFRESA." Shares +1.5% AH. (PR)
Comments (1)
  • Doesn't this make the "beats estimates" a joke? They had NO revenue and still they beat estimates. I guess they did lose less than what was thought possible but please! Can someone give an alternate explanation?
    2 Nov 2009, 04:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)